Article Text

PDF

A depression management programme increased depression free days and costs in depressed frequent users of general health care
  1. Robert Peveler, MA, DPhil, BM, BCh
  1. University of Southampton and Royal South Hants Hospital Southampton, UK

    Statistics from Altmetric.com

    
 
 QUESTION: In depressed patients who are frequent healthcare users, what is the incremental cost effectiveness of a depression management programme (DMP)?

    Design

    Cost effectiveness analysis of a cluster randomised {allocation concealed*}, partially blinded (telephone assessment),* controlled trial with 12 months follow up.

    Setting

    3 health maintenance organisations (HMOs) in the US.

    Patients

    407 patients (mean age 45 y, 77% women) who were frequent users of general medical care (>85th centile for the number of outpatient visits in each of the previous 2 y) and were depressed (Hamilton Depression Rating Scale [HDRS] score ≥15). Exclusion criteria included active treatment for depression in the previous 90 days or contraindications to depression treatment. Analyses included 92% of patients for healthcare use and 91% for cost effectiveness.

    Intervention

    {82} physician practices were allocated to a DMP (n=218), and {81} were allocated to usual care (n=189). DMP consisted of patient and physician education and telephone care management, antidepressant treatment for most patients, and psychiatric consultation for non-responders.

    Main cost and outcome measures

    The main outcome was number of depression free days (estimated by interpolation). Direct costs were assessed for all services provided or paid for by health plans in 1996 US dollars. Costs for time in treatment were estimated as lost wages. Results were adjusted for age, sex, study site, baseline measures of depression severity and health status, and clustering of patients by physicians.

    Main results

    The DMP group had more depression free days than the usual care group (229.3 v 181.9 d; mean adjusted difference 47.4 d, 95% CI 26.6 to 68.2 d). The table shows the incremental costs of the DMP relative to usual care.

    Incremental cost of a depression management programme relative to usual care

    Conclusions

    In depressed patients who are frequent users of general health care, a depression management programme was effective for improving clinical outcomes at increased health services cost. Outpatient and inpatient services each cost approximately $20 per additional depression free day.

    Commentary

    Depressive illness is common and disabling and is mostly managed in primary care without recourse to specialist services. Received wisdom is that management is suboptimal: up to 50% of depressive conditions are missed by practitioners, and treatment of diagnosed patients is of inadequate intensity and duration. Educational interventions for practitioners that use clinical guidelines to improve recognition and management have been evaluated, but they have shown no benefit.

    At least 3 hypotheses may explain this failure: education may be insufficient to change practitioner behaviour, study design may have been inadequate to detect true benefit, or the principles on which guidelines are based may be at fault. The last reason is likely because most of the evidence base comes from secondary care, reflecting a lack of research in primary care. “Sensitivity” of practitioners has been emphasised at the expense of “specificity,” which may result in a failure to target patients who would benefit most from more intensive management.

    The studies by Katzelnick et al and Simon et al report the efficacy and cost effectiveness of a practice based intervention to improve depression management in the managed care context of 3 US HMOs. In a 2 stage screening procedure, patients with consultation rates above the 85th centile for ≥2 years were identified, and those in whom evidence existed of untreated depressive disorder (Diagnostic and Statistical Manual, Fourth Edition, diagnosis and HDRS score ≥15) were recruited (about 5% of the total registered population). Half the sample had ≥1 comorbid chronic physical illness, presumably accounting in part for their high consultation rates. The study had high completion rates, but only patients enrolled with the HMO for ≥2 years were eligible. This study characteristic limits the generalisability of the work to other settings (such as general practice) and biases the results against such groups as the long term unemployed or the elderly.

    DMPs have already been shown to be of benefit to unselected depressed patients in primary care. In this study, patients in the DMP had better outcomes than those receiving usual care, with significantly greater reductions in depression scores and higher quality of life ratings. The authors estimate a number needed to treat of 5 to achieve 1 additional remission, although it is not clear how remission was defined for this calculation. The 2 studies were screening studies, however, and the “number needed to screen” to achieve 1 additional remission is close to 17. Consultation rates in the intervention group increased, whereas those in the usual care group decreased slightly.

    It is not possible to identify which component of the programme was most beneficial, but it seems probable on clinical grounds that the initial visit for assessment and initiation of management (which did not occur in the usual care group) would have had considerable effect.

    In analysing the cost effectiveness of the programme, the construct of “depression free days” was used. It is important to understand how these days were derived. As depression scores were only assessed at 6 weeks and 3, 6, and 12 months, most of the data were interpolated. HDRS scores ≤7 were taken as “depression free” (score 0), whereas scores ≥22 were taken as “fully symptomatic” (score 1). Linear interpolation was used to model recovery, allowing calculation of a number between 0 and 1 for each day; “depression free days” were then calculated by dividing the total scores by the number of days in the period between estimates. This construct is clearly notional, and its name is misleading because many of the periods contained no true depression free days, only partial depression free days.

    The costs of the intervention appear high, and no evidence existed of the hoped for “cost offset” effect by reduction in other sources of healthcare costs, perhaps not surprising given the high prevalence of comorbid physical illness. The authors observe that the study was insufficiently powered to compare frequency of inpatient admission, which is costly; this lack might have led to failure to detect benefits. The study also had only a 1 year follow up, and benefits may take longer to be detected.

    The clinical bottom line is that it is possible to identify unmet needs and improve outcomes in this segment of the primary care population, but substantial additional resources are required. Although these are not out of line with the costs of treating other important conditions, priorities have to be established to permit shifting of existing resources away from other therapeutic areas or investment of greater resources in this one.

    View Abstract

    Footnotes

    • Source of funding: Pfizer Pharmaceuticals.

    • For correspondence: Dr G E Simon, Center for Health Studies, Group Health Cooperative, 1730 Minor Avenue, Suite 1600, Seattle, WA 98101-1448, USA. Fax +1 206 287 2871.

    • Abstract and commentary also appear in Evidence-Based Mental Health.

    • * See glossary.

    • Information provided by author.

    • Katzelnick DJ, Simon GE, Pearson SD, et al. Arch Fam Med 2000;9:345–51.

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.